Research programme: sexual dysfunction therapy - Melacure

Drug Profile

Research programme: sexual dysfunction therapy - Melacure

Alternative Names: Sexual dysfunction therapy research programme - Melacure

Latest Information Update: 02 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Melacure Therapeutics (CEASED)
  • Class
  • Mechanism of Action Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Female sexual dysfunction; Male sexual dysfunction

Most Recent Events

  • 02 Aug 2006 No development reported - Preclinical for Female sexual dysfunction in Sweden (unspecified route)
  • 02 Aug 2006 No development reported - Preclinical for Male sexual dysfunction in Sweden (unspecified route)
  • 16 Jul 2003 Preclinical trials in Female sexual dysfunction in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top